Reply  by Matsumura, Jon S. et al.
a rate that seems preposterously high. If that is so, how can that
group have had a survival rate that is as good or better than the
EVAR group? These sources of confusion, as well as a lack of
disclosure of what themajor adverse events actually were, lead us to
conclude that the study does not show anything specific about
EVAR with the EXCLUDER device or that it has “fewer major
adverse events compared with open repair.”
Michael S. McMurtry, MD, PhD
Joshua A. Beckman, MD, MSc
Brigham and Women’s Hospital
Boston, Mass
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Reply
We are pleased that Drs McMurtry and Beckman were inter-
ested in the 5-year report1 and appreciate the opportunity to
respond. Of the original 235 test patients, 128 entered the final
5-year interval. The 107 test patients that were not available
included 54 patients who died, 30 patients who withdrew consent,
and 23 patients whowere unavailable for other reasons. Those with
experience performing these long-term studies recognize the dif-
ficulties of retaining enrollment of these elderly patients with
considerable medical problems. The original power analysis antic-
ipated a 6.5% annual mortality and 8% annual lost to follow-up. In
retrospect, these predictions were remarkably accurate, although
we had fewer patients lost to follow-up than predicted due to the
conscientious work of the site coordinators and investigators.
Despite the attrition, there were enough subjects in each group to
show a statistically significant difference between test and control
arms in freedom from any major adverse event after 5 years.
Many of your “other large sources of confusion” can be
clarified by reading the previously published and referenced 2-year
results.2 Specifically, “adverse events were stratified by severity into
minor and major adverse events by published criteria, and this
stratification was reviewed by a Clinical Events Committee.” Fur-
ther details on the criteria for adjudication and the categories of
these early events are provided in the methods section and Table
IV. Categories of later major adverse events are given in the Table
below. The Clinical Events Committee was a multispecialty group
that was blinded as much as possible and applied reporting stan-
dards published at the time of study initiation–the Sacks criteria.3
The blinding process helps avoid biased adjudication of adverse
events as your comment on “preposterously high” reveals that
there are clearly preconceived biases of the safety of the control
treatment. As detailed in the discussion, further analysis of minor,
major, and total complications was performed to determine
whether the Sacks criteria obscured differences between groups.
There were significantly fewer complications in the test group
regardless of the stratification by severity. In fact, the early major
adverse event rates using these published criteria were 14% of test
group vs 57% of control group, not “nearly 70%” that you claim.
The nonrandomized nature of this trial is a limitation that was
addressed by performing a multivariable analysis including known
differences in the two groups. This showed that test group was still
a strong independent predictor for fewer major adverse events.
Your query regarding the difference in major adverse events not
being associated with differences in mortality is simply answered by
the reality that vascular surgeons recognize and treat postoperative
complications effectively. These adverse events often prolong hospi-
talization and recovery as was demonstrated in differences in clinical
utility, but fortunately do not often lead to mortality.
The goal of this 5-year report was not to reiterate findings
previously found in the 2-year results, but rather to determine if
reinterventions and late events in the test group resulted in loss of
the early benefits seen after endovascular abdominal aortic aneu-
rysm repair. We stand by our conclusions that after 5 years,
endovascular repair has fewer major adverse events despite includ-
ing late reinterventions when compared with open repair.
Sincerely,
Table. Categories of late major adverse events
Year 1-after
30 d Year 2 Year 3 Year 4 Year 5
Test Control Test Control Test Control Test Control Test Control
Subjects evaluable 232 97 213 82 185 71 161 61 128 47
Subjects with one or more MAE 68 23 55 15 33 8 29 15 15 5
Bleeding complications 1 — 1 — 1 — 3 1 — —
Endoleak requiring intervention 13 — 10 — 2 — 3 — — —
Pulmonary complications 10 4 4 2 5 1 7 4 4 1
Cardiac complications 16 13 18 8 11 3 6 8 7 3
Genitourinary complications 6 2 — — — — 3 — 1 —
Sepsis 1 — — — 1 — 1 — — —
Neoplasm 7 1 8 2 5 3 4 — — —
Renal complications 5 — 4 1 3 1 2 3 1 —
Wound complications 8 3 1 1 2 2 1 1 — —
Bowel complications 8 3 7 1 2 1 2 2 1 1
Vascular complications 7 4 1 2 2 — 2 — 1 1
Neurologic complications 8 5 6 1 4 — 2 2 1 —
Other complications 12 2 11 3 8 1 7 3 1 —
Death (unknown cause) — — — — — — 1 — — —
Increase in aneurysm requiring
intervention (with or without endoleak) 1 — 8 — 1 — 6 — 2 —
MAE, Major adverse events.
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CORRECTION
For the article “Acute aortic dissection associated with use of cocaine” published in J Vasc Surg 2007;46:427, Scott
A. Lemaire, MD, should have been listed as a co-author.
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